Age Management

Regenerative Medicine For Age Management | Stemedix
Regenerative Medicine For Age Management | Stemedix

Regenerative Medicine for Age Management

Explore regenerative medicine research and evidence-based strategies to help support healthy aging.

Contact a Care Coordinator

Content Review: Michael Healey, M.Ed., C.A.S. Last Updated: September 2026

Understanding the Science of Aging

Aging is a gradual biological process that affects every organ and tissue over time. Changes in cellular repair, energy production, inflammation, hormone signaling, muscle mass, bone density, skin structure, and nervous-system function can all contribute to how people feel and function as they get older.

Aging itself is not a disease, and no treatment has been shown to stop or reverse normal human aging. However, healthy-aging strategies can help preserve function, reduce disease risk, and support quality of life. Regenerative medicine research is also examining whether cell-based and cell-derived approaches may influence specific age-related conditions.

How Aging Affects the Body

  • Changes in vision or hearing
  • Reduced muscle mass, strength, or physical endurance
  • Joint stiffness or slower recovery after activity
  • Changes in sleep quality or energy levels
  • Skin thinning, dryness, wrinkles, or reduced elasticity
  • Changes in memory, processing speed, or concentration
  • Bladder, bowel, or sexual-health changes
  • Greater vulnerability to illness, injury, or physical stress

These changes do not occur at the same rate in everyone. Genetics, chronic medical conditions, physical activity, nutrition, sleep, tobacco and alcohol exposure, medications, social factors, and other health behaviors all influence how aging affects the body.

Traditional Approaches to Age Management

A Modern Regenerative Approach

Recent Human Studies on Umbilical Cord MSCs and Exosomes

2025: Laromestrocel Trial Met Its Safety Endpoint and Reported Signals in Mild Alzheimer’s Disease

Allogeneic Mesenchymal Stem Cell Therapy With Laromestrocel in Mild Alzheimer’s Disease: A Randomized Controlled Phase 2a Trial — Read Study

This randomized, double-blind, placebo-controlled phase 2a trial evaluated laromestrocel, a bone-marrow-derived allogeneic mesenchymal cell therapy, in 49 treated participants with mild Alzheimer’s disease. The study met its primary safety endpoint, with similar rates of treatment-emergent serious adverse events across groups and no reported infusion-related reactions, hypersensitivity reactions, or amyloid-related imaging abnormalities. At 39 weeks, investigators also reported favorable signals in several secondary and exploratory measures, including a composite Alzheimer’s disease score, selected cognitive and daily-living measures, whole-brain volume, hippocampal volume, and neuroinflammation imaging. These findings provide encouraging phase 2a evidence supporting continued clinical development of laromestrocel for mild Alzheimer’s disease. They should not be interpreted as evidence that MSC therapy slows normal cognitive aging or provides a general anti-aging effect in healthy adults.

2024: Randomized Frailty Trial Reported Improvements in Quality of Life and Physical Performance

Safety and Efficacy of Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in the Treatment of Patients With Aging Frailty: A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study — Read Study

This phase I/II trial randomly assigned 30 adults ages 60 to 80 with aging frailty to receive two intravenous infusions of human umbilical-cord-derived MSCs or placebo one month apart. At six months, the MSC group showed a greater improvement in the physical-component score of the SF-36 quality-of-life measure than the placebo group, along with favorable differences in EQ-VAS scores, timed-up-and-go performance, grip strength, and inflammatory markers including TNF-α and IL-17. The 4-meter walking-time difference favored MSC treatment but was not statistically significant, and no serious adverse events were observed. The randomized, placebo-controlled design and favorable six-month safety and functional findings make this an important human study of MSC therapy in aging frailty, though larger studies are still needed to confirm the magnitude, durability, and clinical significance of these effects.

2024: Review Summarized Early Exosome Research in Cosmetic Dermatology

Clinical Applications of Exosomes in Cosmetic Dermatology — Read Review

This 2024 review evaluated published human and animal research on exosomes in regenerative and cosmetic dermatology, identifying four prospective clinical trials focused on skin rejuvenation while emphasizing that clinical evidence remains limited. One study summarized in the review was a 2023 prospective, randomized, split-face study involving 28 adults with facial skin aging, in which one side of the face received microneedling with a human adipose-stem-cell-derived exosome-containing solution while the other side received microneedling with saline. At 12 weeks, the exosome-treated side showed greater improvements in wrinkle measurements, elasticity, hydration, melanin index, and histologic collagen and elastic-fiber density, with mild and temporary reported adverse effects. These early findings support continued investigation of extracellular-vesicle products in cosmetic dermatology, though the review cautioned that product sourcing and preparation are not standardized and exosome products have not received FDA approval.

Age Management Alternative | Stemedix
Age Management Alternative | Stemedix

Considering Regenerative Medicine for Age Management

Medical Disclaimer

This page is for educational purposes only and does not constitute medical advice.
Stem cell, exosome, and other regenerative medicine therapies for general age management are not FDA-approved for this use, and findings from studies in frailty, Alzheimer’s disease, or cosmetic dermatology do not establish benefits for normal aging or longevity in healthy adults.
Always consult a qualified healthcare professional before starting, stopping, or modifying any medical, hormone, supplement, cosmetic, or regenerative treatment.

References

  1. Rash BG. et al. Allogeneic Mesenchymal Stem Cell Therapy With Laromestrocel in Mild Alzheimer’s Disease: A Randomized Controlled Phase 2a Trial. Nature Medicine., 2025. Full Text
  2. Zhu Y. et al. Safety and Efficacy of Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in the Treatment of Patients With Aging Frailty: A Phase I/II RCT. Stem Cell Research & Therapy., 2024. Full Text
  3. Clinical Applications of Exosomes in Cosmetic Dermatology. Skin Health and Disease., 2024. Full Text
  4. Park GH. et al. Efficacy of Combined Treatment With Human Adipose Tissue Stem Cell-Derived Exosome-Containing Solution and Microneedling for Facial Skin Aging: A 12-Week Prospective, Randomized, Split-Face Study. Journal of Cosmetic Dermatology., 2023. Full Text

U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies.

Speak with a Care Coordinator today for a more accurate assessment of your condition and therapy options.

Speak with a Care Coordinator

Forward-Thinking Medicine for Age Management

Contact us today and let Stemedix provide a professional service accompanied by one of our Care Coordinators to ensure you have the best experience possible!

Contact a Care Coordinator
Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.